Harvard College

Ucb Biopharma Sprl

Adrian Richard Moore

Ralph Adams

Kerry Louise Tyson

Carl Brendan Doyle

Karine Jeannine Madeleine Hervé

Gökhan S Hotamisligil

Mehmet F Burak

Shauna Mhairi Wales

Feyza Engin

Scott B Widenmaier

Elisabeth Helen Roberts

Karen Inouye

This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as 'aP2') for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.

Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders

Anti-aP2 antibodies and antigen binding agents to treat metabolic disorders

Growing community of inventors

Slough, United Kingdom

Adrian Richard Moore